{"id":"ole-bsa-adalimumab-mtx","safety":{"commonSideEffects":[{"rate":"12-20","effect":"Injection site reactions"},{"rate":"7-10","effect":"Upper respiratory tract infections"},{"rate":"5-8","effect":"Headache"},{"rate":"0.1-0.5","effect":"Tuberculosis reactivation"},{"rate":"2-4","effect":"Serious infections"},{"rate":null,"effect":"Malignancy risk (increased)"}]},"_chembl":{"chemblId":"CHEMBL1201580","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adalimumab is a fully human monoclonal antibody that binds to and neutralizes TNF-alpha, a key pro-inflammatory cytokine. By blocking TNF-alpha, it suppresses the inflammatory cascade underlying autoimmune diseases. The addition of methotrexate (MTX) provides synergistic immunosuppression and is commonly used in combination therapy for rheumatoid arthritis and other inflammatory conditions.","oneSentence":"Adalimumab is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha signaling to reduce inflammation, with optional methotrexate co-administration to enhance efficacy.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:58.067Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis (with or without methotrexate)"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Plaque psoriasis"}]},"trialDetails":[{"nctId":"NCT00048542","phase":"PHASE3","title":"Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)","status":"COMPLETED","sponsor":"Abbott","startDate":"2002-09","conditions":"Arthritis, Juvenile Idiopathic","enrollment":171}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ABT-D2E7","Humira"],"phase":"phase_3","status":"active","brandName":"OLE BSA Adalimumab +/- MTX","genericName":"OLE BSA Adalimumab +/- MTX","companyName":"Abbott","companyId":"abbott","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adalimumab is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha signaling to reduce inflammation, with optional methotrexate co-administration to enhance efficacy. Used for Rheumatoid arthritis (with or without methotrexate), Ankylosing spondylitis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}